Gut Mucosa in HIV Infection: “Immune Milk” Solution

In recent weeks, three noteworthy papers, published in PLoS Medicine, The Journal of Virology, and Nature Medicine, direct our attention to the gut as a critical target in HIV-1 infection and portal for therapeutic intervention. 
 
In PLoS Medicine, Mehandru and colleagues report that over half of the CD4+ T cells in the gut mucosa are lost within the first few weeks after HIV-1 infection and remain consistently low, compared to peripheral blood sources, despite long term antiretroviral therapy; furthermore, of the few CD4+ T cells that persist in the gut, a significant increase in immune activation is observed [1]. Consistent with earlier observation in SIV models, Veazey reminds us that the battle against HIV-1 should focus on the intestinal mucosa with therapeutic strategies to reduce gut immune activation [2]. 
 
The longitudinal study in The Journal of Virology by Guadalupe and colleagues showed a similar discordance in CD4+ T cells between restoration in peripheral blood and significant delay in the gut mucosa of chronic infected individuals during antiretroviral therapy. Here, the depletion in CD4+ T cells was associated with an increase in gut immune activation, CD8+ T cells, and associated inflammation with a corresponding decease in epithelial growth and repair-associated genes in gut mucosal tissue [3]. Brenchley and colleagues suggest in Nature Medicine that HIV infection causes this breakdown in the gut mucosa resulting in a “leaky gut,” thus allowing translocation of gut-derived endotoxin and the subsequent triggering of immune activation [4]. 
 
Collectively, these observations suggest that an orally active therapeutic, used in conjunction with antiretroviral therapy, be designed to both block gut-derived microbial translocation and stimulate restitution of the gut epithelium. The hope would be to restore immunological integrity of the intestinal mucosal barrier, thereby controlling immune activation, both locally, in the gut mucosa, and systemically by suppressing cellular targets distal to the gut that may directly contribute to the progression of AIDS [5–8]. 
 
The design for such an orally active therapeutic may be found in the complex formula of bovine colostrum and “immune milk,” which has long been recognized to offer passive protection from a broad number of enteric bacterial and viral pathogens, primarily via the transfer of immunoglobulins and suppression of gut-associated inflammation with promotion of mucosal repair and regeneration. 
 
The gut in chronic HIV-1-infected individuals appears to be reminiscent of newborn calves. Calves are born with a highly immature mucosal immune system and “leaky gut” which, if not immediately corrected, results in death due to infection and associated systemic immune activation. However, the cow's first milk rescues her calves from harmful gut microbes with a uniquely complex cocktail enriched with neutralizing polyclonal antibodies, cytokine tissue repair factors, and immune enhancing probiotics, such as Lactobacillus species. 
 
Regular consumption of biologically active bovine colostrum has been known for years to promote the development of infantile gut-associated lymphoid tissue and enhance CD4+ levels, while suppressing CD8+ and inflammatory bowl disease (IBD), including ulcerative colitis and Crohn disease [5]. The severity of IBD is often correlated with gut microbial-endotoxin translocation, which now appears in chronic HIV-1-infected individuals [4]. Similar to bovine colostrum, “immune milk” from properly vaccinated cows affords passive immunity against bacterial, viral, and fungal infections in the human gastrointestinal tract, as well as taming gut inflammation [8]. 
 
Hence, there may be lessons learned from Bessie's “immune milk.” If viewed as a unique formula that has evolved to complement gut immunity, “immune milk” may also provide relief in chronic HIV-infected individuals. Initial studies have already shown that ingestion of colostrum alleviates refractory diarrhea in HIV patients with a corresponding increase in both body weight and peripheral blood CD4+ T cells [9,10]. As we learn more about the gut microenvironment in HIV-infected individuals, Bessie may prove to be a worthwhile platform for the consideration of “immune milk” exhibiting both microbial endotoxin and HIV-neutralizing activity along with its innate anti-inflammatory and tissue repair and regenerative properties.

Copyright: © 2007 Amir Attaran.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding:
The author received no specifi c funding for this article.
Competing Interests: In 2003, the World Bank commissioned AA to write about AIDS drug procurement and resistance.In 2001, he coauthored an editorial for the Washington Post calling for Andrew Natsios' resignation.AA was the Academic Editor on the study in PLoS Medicine commented on in this letter [4], and collaborated with several of the study authors on a second systematic review of adherence to HIV medicines [3].

"The Right Stuff": The Global Burden of Disease Bolajoko O. Olusanya
PLoS Medicine is one of the few journals with a dedicated forum for neglected diseases, and the suggestion by its editors that journals should give preference to diseases based on their relative contributions to the global burden of disease is noteworthy as a positive step towards optimising the global research agenda [1].Undoubtedly, the recent report by Mathers and Loncar, like earlier versions of the Global Burden of Disease (GBD) study, represents the best effort yet at providing a level playing fi eld for diverse diseases and health conditions globally [2].A key feature of this project is the evaluation of health outcomes in terms of mortality and burden of disease indexed by disability-adjusted life years (DALYs).However, a few concerns still linger on the application and current scope of the study which have signifi cant implications for health-care policy, particularly in the developing world.The concept of the "burden of disease" was introduced to redress the inequality and inequity occasioned by the exclusive use of mortality as the summary measure of population health [3,4].The DALY was thus intended to provide information on non-fatal health outcomes of diseases that have been largely neglected in health planning because of the "conceptual and defi nitional complexity of measuring morbidity and disability in populations" [5].However, it is uncertain how far the well-intentioned paradigm shift in disease evaluation has been achieved, as global health initiatives are still rarely concerned with reduction in "burden of disease" besides mortality.This is also applicable to health planning at country or community level.In fact, the signifi cance of noncommunicable/chronic health conditions such as cardiovascular diseases, cancer, diabetes, and mental illness is still being predominantly promoted on the basis of case fatality rather than disease burden.Conceptually, DALY and its variants like quality-adjusted life years (QALYs) represent equitable measures of population health that should be more actively promoted, but more work is required to address some of the methodological and equity concerns that have been raised since their introduction to global health [6,7].
The continued ranking of childhood diseases alongside adult diseases in the GBD report often portrays children as "young adults".This practice distracts from diseases and conditions that have signifi cant impacts on optimal early childhood development.Moreover, the risk of death for children younger than fi ve years is projected to fall by more than 40% between 2005 and 2030, while life expectancy globally is expected to improve signifi cantly by 2030, with the largest increases occurring in Africa and South Asia [1].This trend is likely to bring to the fore the neglected discourse on the quality of life for the many survivors of acute childhood illnesses, particularly as the years lived with disability for chronic diseases of childhood onset far exceed those of adult onset.For instance, it is diffi cult to justify the continued failure to address a highly preventable perinatal condition such as neonatal jaundice, which may not be a leading cause of mortality but currently causes substantial burden in lowincome countries [8].
Similarly, hearing loss of adult onset remains one of the ten leading causes of DALYs globally, particularly in highincome and middle-income countries, but is not expected to be a leading health problem in low-income countries by 2030 [1].While this is gratifying to note, the current trend in the prevalence of disabling hearing loss (which more than doubled from 120 million in 1995 to about 278 million persons in 2005, two-thirds of whom reside in developing countries) may have much greater impact than projected, considering the envisaged improvement in life expectancy [9].But more importantly, the exclusion of hearing loss of childhood onset or the failure to adequately account for permanent childhood hearing loss in these projections underrepresents the true burden of hearing loss.It disfranchises about 718,000 babies born annually in the developing world with neonatal hearing loss from available time-bound early detection and intervention services now a standard of neonatal care in developed countries [10].
The call by Mathers and Loncar for more robust studies across the regions of the world must not be overlooked or considered lightly.As new evidence emerges from such studies, the projected trend and ranking in many countries may ultimately differ from the overall global and regional picture in the current GBD report.Meanwhile, systematic steps to address these and other concerns should be considered urgently to effectively promote the concept of the burden of disease.Invariably, we all need to be guided by a variety of sources and perspectives in determining "the right stuff" for the heterogeneous populations of the world.

Funding:
The author received no specifi c funding for this article.
Competing Interests: The author has declared that no competing interests exist.

Gut Mucosa in HIV Infection: "Immune Milk" Solution Shawn J. Green
In recent weeks, three noteworthy papers, published in PLoS Medicine, The Journal of Virology, and Nature Medicine, direct our attention to the gut as a critical target in HIV-1 infection and portal for therapeutic intervention.
In PLoS Medicine, Mehandru and colleagues report that over half of the CD4 + T cells in the gut mucosa are lost within the fi rst few weeks after HIV-1 infection and remain consistently low, compared to peripheral blood sources, despite long term antiretroviral therapy; furthermore, of the few CD4 + T cells that persist in the gut, a signifi cant increase in immune activation is observed [1].Consistent with earlier observation in SIV models, Veazey reminds us that the battle against HIV-1 should focus on the intestinal mucosa with therapeutic strategies to reduce gut immune activation [2].
The longitudinal study in The Journal of Virology by Guadalupe and colleagues showed a similar discordance in CD4 + T cells between restoration in peripheral blood and signifi cant delay in the gut mucosa of chronic infected individuals during antiretroviral therapy.Here, the depletion in CD4 + T cells was associated with an increase in gut immune activation, CD8 + T cells, and associated infl ammation with a corresponding decease in epithelial growth and repairassociated genes in gut mucosal tissue [3].Brenchley and colleagues suggest in Nature Medicine that HIV infection causes this breakdown in the gut mucosa resulting in a "leaky gut," thus allowing translocation of gut-derived endotoxin and the subsequent triggering of immune activation [4].
Collectively, these observations suggest that an orally active therapeutic, used in conjunction with antiretroviral therapy, be designed to both block gut-derived microbial translocation and stimulate restitution of the gut epithelium.The hope would be to restore immunological integrity of the intestinal mucosal barrier, thereby controlling immune activation, both locally, in the gut mucosa, and systemically by suppressing cellular targets distal to the gut that may directly contribute to the progression of AIDS [5][6][7][8].
The design for such an orally active therapeutic may be found in the complex formula of bovine colostrum and "immune milk," which has long been recognized to offer passive protection from a broad number of enteric bacterial and viral pathogens, primarily via the transfer of immunoglobulins and suppression of gut-associated infl ammation with promotion of mucosal repair and regeneration.
The gut in chronic HIV-1-infected individuals appears to be reminiscent of newborn calves.Calves are born with a highly immature mucosal immune system and "leaky gut" which, if not immediately corrected, results in death due to infection and associated systemic immune activation.However, the cow's fi rst milk rescues her calves from harmful gut microbes with a uniquely complex cocktail enriched with neutralizing polyclonal antibodies, cytokine tissue repair factors, and immune enhancing probiotics, such as Lactobacillus species.
Regular consumption of biologically active bovine colostrum has been known for years to promote the development of infantile gut-associated lymphoid tissue and enhance CD4 + levels, while suppressing CD8 + and infl ammatory bowl disease (IBD), including ulcerative colitis and Crohn disease [5].The severity of IBD is often correlated with gut microbial-endotoxin translocation, which now appears in chronic HIV-1-infected individuals [4].Similar to bovine colostrum, "immune milk" from properly vaccinated cows affords passive immunity against bacterial, viral, and fungal infections in the human gastrointestinal tract, as well as taming gut infl ammation [8].
Hence, there may be lessons learned from Bessie's "immune milk."If viewed as a unique formula that has evolved to complement gut immunity, "immune milk" may also provide relief in chronic HIV-infected individuals.Initial studies have already shown that ingestion of colostrum alleviates refractory diarrhea in HIV patients with a corresponding increase in both body weight and peripheral blood CD4 + T cells [9,10].As we learn more about the gut microenvironment in HIV-infected individuals, Bessie may prove to be a worthwhile platform for the consideration of "immune milk" exhibiting both microbial endotoxin and HIV-neutralizing activity along with its innate antiinfl ammatory and tissue repair and regenerative properties.Shawn J. Green (shawng@origobiosciences.com)  [2].Their abilities in the critical analysis of drug promotional materials are evaluated during the pharmacology practical examination.The students are also taught to critically evaluate drug promotion by medical representatives (MRs) using the medium of role-play [3].The four recommendations made by the authors are important, but developing countries may face problems in their implementation.We recommend that all health professionals be educated about decision making and evaluation of evidence and promotion.Our department runs a drug information center in the teaching hospital and we are trying to use this center to promote evidence-based medicine.However, there are no formal courses on evaluating the evidence.Doctors do not have an adequate knowledge of statistics to arrive at evidence-based decisions.
The authors' second and third recommendations pose further problems.Conferences in Nepal continue to be heavily sponsored by the pharmaceutical industry.MRs have unrestricted access to doctors in our hospital and in most other hospitals in Nepal.One-to-one visits, personal gifts, and other methods of sponsorship are the norm.Academic detailing is absent.I am personally ambivalent about banning one-to-one detailing.Many health professionals in South Asia are in private practice or work in small hospitals.It is an unfortunate fact, but MRs may be their only source of information about medicines.Banning MRs may deprive them of this source, however biased it may be.Exposing students to misleading presentation, fostering false beliefs, debunking these beliefs, and explaining the misleading techniques is an effective approach, used in our department during teaching critical evaluation of medicinal drug promotion.
We have had mixed success regarding educating health professionals to avoid promotion or look at it critically.We have been able to infl uence students during the fi rst two years of their training.The infl uence of our training is considerably eroded once students are in their clinical phase.Enlisting the support of clinicians, making them aware of irrational promotion, and using their services to teach doctors in training is vital if we are to make progress.Education regarding the most reliable sources of information is lacking in South Asia.Health organizations, professional associations, and other bodies should develop information sources which are readily accessible to prescribers.Western information sources may have many limitations in developing countries.
So far, no medical student organizations in Nepal have taken up the issue of pharmaceutical promotion.The curriculum of Kathmandu University recommends teaching students to assess promotional materials.However, many medical schools do not address this vital issue.Meanwhile, the Nepalese pharmaceutical industry is coming of age.The pharmaceutical giants based in our Southern neighbor, India, are also active in Nepal.It is time for medical professionals to get their act together to ensure a proper relationship with the industry.

Funding:
The author received no specifi c funding for this article.

Competing Interests:
The author has declared that no competing interests exist.

Educating Health Professionals about Drug and Device Promotion: Authors' Reply
We thank Prof. Ravi Shankar for his thoughtful refl ections [1] on our recommendations for education about drug and device promotion [2].Prof. Shankar is one of the few who have published an evaluation of education about drug promotion [3], so we are pleased that he concurs with most of our recommendations.We agree with him that implementation of our recommendations will be diffi cult.The main barrier to implementation is the widespread denial by health professionals that we are often adversely infl uenced by promotion.This denial arises partly from ignorance of the evidence about promotion and partly from a refusal to accept that evidence, because it is viewed as insulting our self-esteem [4].We believe health professionals need to move from overconfi dent illusions of invulnerability to accept that we are human, so it is normal for us to be misled by persuasive promotional techniques [5].
Prof. Shankar seems to believe that doctors can be taught to "critically evaluate drug promotion" [1] so as to "optimise time spent with medical representatives" [3], although he acknowledges only "mixed success" with his medical students [1].By contrast, we are pessimistic that doctors will ever be able to gain more good than harm from visits by sales representatives in any country.All the relevant evidence of which we are aware suggests that exposure to promotion correlates with less appropriate prescribing [6].Furthermore, the skills required to avoid being misled may take many years to learn, and many hours to apply after each visit.There is no proven method for overcoming normal human vulnerabilities such as the tendency to believe attractive, socially skilled people, especially if they have built up trust over many visits.Consequently, we believe the onus is on anyone who claims that it is possible for health professionals to learn how to gain net benefi t from sales representatives' visits to produce evidence to support that claim.
Prof. Shankar is ambivalent about our recommendation that health professionals avoid promotion because in his country, Nepal, sales representatives "may be their only source of information about medicines."We share Shankar's concern about lack of relevant independent information for doctors in many countries.In all countries, whoever pays for health care will get better results at lower cost by funding independent information, rather than paying direct and indirect costs from inappropriate drug and device use caused by misleading promotion.Payers for health care are more likely to fund such initiatives if they understand how harmful drug promotion is.Even if no such initiatives are forthcoming, we reject the idea that any information-even if it is misleading-is better than no information at all.The majority of new drugs are more expensive than their older analogues, but no better (and sometimes worse).Patients would be better off if doctors were ignorant non-prescribers of such drugs rather than misinformed frequent prescribers.
Current patterns of health professionals' interactions with the drug and device industry are causing much harm [6].Our three main tasks are to develop optimal recommendations for improvement, identify barriers to implementation, and develop methods for overcoming those barriers.We appreciate any input, including Prof. Shankar's refl ections, that will help us improve our performance on those tasks.
Peter R. Mansfi eld (peter@healthyskepticism.org)We wholeheartedly agree with Paul Farmer and colleagues [1] that it is vitally important to examine social, as well as molecular, causes of disease.Unless we carefully consider the full range of factors that underlie a given problem, we may produce "solutions" with unintended and deleterious consequences.In this light we express our concern about the infant feeding approach advocated in their article to reduce mother-to-child transmission of HIV in Rwanda.
While exclusive replacement feeding reduces the risk of transmission between HIV-positive mothers and their infants, it does not adequately address the specters of infection and undernutrition that accompany avoidance of breast-feeding.We are convinced-by data from regions that are similar to Rwanda and even from African countries with higher standards of living-that replacement feeding from birth is a dangerous and inappropriate approach for HIV-affected families in countries like Rwanda.
In addition, avoiding breast-feeding from birth can be exceedingly risky, particularly in the same regions where the risk of mother-to-child transmission of HIV is highest.While Partners in Health (PIH) offers high-quality healthcare support and fi nancial assistance to reduce the risks associated with breast-feeding avoidance in two districts in Rwanda, it is impossible to eliminate those risks.Researchers have found that children in Ghana, Peru, and India who are not breast-fed between the ages of six weeks and six months have a ten-fold higher risk of death [2].A multi-country analysis by the World Health Organization (WHO) showed that infants who were born to mothers with little education and were not breast-fed had a fi ve-fold increased risk of death from six to 11 months of age.Since about 5% of breast-fed Rwandan babies already die in the fi rst six months of life and another 3.5% from six to12 months [3], it is essential that PIH substantiate the mortality, nutrition, and morbidity outcomes resulting from their approach before promoting it more widely.
Given that breast-feeding avoidance increases the risk of death from other causes, even as it decreases the risk of HIV transmission, is there a net gain?The concept of "HIVfree survival" combines the likelihood of surviving with the likelihood of not becoming HIV infected, allowing a more comprehensive assessment of the risks and benefi ts of infant feeding.In Botswana [4] and the Ivory Coast [5], rates of HIV-free survival were no better among formula-fed infants than among infants breast-fed for three to six months.At this year's WHO Consultation on HIV and Infant Feeding in Geneva, reports showed high death rates in ongoing trials in Kenya, Uganda, and Malawi associated with breast-feeding cessation at three to six months.These results were despite earlier assumptions that breast-feeding cessation at this age might be safe, while avoiding most of the HIV transmission associated with prolonged breast-feeding [6].Since these carefully controlled studies represent best-case scenarios for replacement feeding, most actual program settings will favor breast-feeding (actually, disfavor replacement feeding).
The risk of mother-to-child HIV transmission in the fi rst six months in a country like Rwanda, where 81% of women are still exclusively breast-feeding at four to six months [3], is relatively low-probably approximately 0.3% per month [7].It may be even lower in districts like those in which PIH works, where eligible HIV-positive mothers begin receiving highly active antiretroviral therapy during pregnancy, because the majority of postnatal HIV transmission is from mothers with low CD4+ cell counts [8].
Scientifi c evidence amply demonstrates the signifi cant risks that accompany replacement feeding and the safety and effectiveness of exclusive breast-feeding for the fi rst six months, and continued breast-feeding thereafter as appropriate and safe.Around the world, researchers, programmers, and policy makers are becoming increasingly convinced that the infant feeding counseling component of prevention of mother-to-child transmission of HIV programs must focus on optimizing HIV-free survival rates, not simply on HIV transmission.Accomplishing this means taking full account of all factors, both social and molecular, that are at work in a particular context, and tailoring responses to meet them.
Ted Greiner (tgreiner@path.org)We thank the authors [1,2] for the two perspectives on our articles [3,4].Our study estimated the prevalence of blindness in Mankien at 4%, which Kuper and Gilbert describe as being "beyond the range" of the studies reviewed by Pascolini et al. [5].The review did not include any studies from the ten states that compose southern Sudan.The nearest surveys reported were conducted in 1998 in Al-Ginena province of Southern Darfur-which is within the 16 northern states of Sudan governed from Khartoum, and was not directly affected by the war in the south.The Al-Ginena studies show a blindness prevalence of 3.2% in all ages [6,7].Yet despite the geographical proximity, two decades of civil war in the south were accompanied by the absence of a health infrastructure, and no preventive health services to speak of, which makes southern Sudan unique.Comparisons with other parts of Sudan or with other countries are probably not justifi ed or meaningful.
Our survey was conducted in Mankien, which was anecdotally known to be endemic for severe blinding trachoma, and this was subsequently confi rmed by our trachoma survey, which showed an overall prevalence of trichiasis and bilateral corneal opacity of 9.6% and 3.1%, respectively [3].The prevalence of blinding cataract in Mankien was consistent with expectation, and would presumably have been higher had there been a systematic over-sampling of the blind.It is the prevalence of blinding trachoma that sets the population apart from all others reported and reviewed by Pascolini et al.These survey data from Mankien are extremely valuable in that they demonstrate the way uncontrolled trachoma can ravage

P
. Ravi Shankar (ravi.dr.shankar@gmail.com)Manipal College of Medical Sciences Pokhara, Nepal Citation: Shankar PR (2007) Educating health professionals about drug and device promotion: A Nepalese perspective.PLoS Med 4(2): e89.doi:10.1371/journal.pmed.0040089Copyright: © 2007 P. Ravi Shankar.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Neurological and developmental outcome of neonatal jaundice and sepsis in rural Kenya.Trop Med Int Health 10: 798-817.9. World Health Organization (2006) Primary ear and hearing care training resource: Advanced level.Available: http:⁄⁄www.who.int/entity/pbd/deafness/activities/hearing_care/advanced.pdf.Accessed 25 January 2007.10.Olusanya BO, Newton VE (2007) Global burden of permanent childhood hearing impairment and disease control priorities for developing countries.Olusanya BO (2007) "The right stuff": The global burden of disease.PLoS Med 4(2): e84.doi:10.1371/journal.pmed.0040084Copyright: © 2007 Bolajoko O. Olusanya.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Lancet: In press.Citation: Cone RA, Whaley KJ (1999) Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.Emerg Infect Dis 5: 54-64.8.Green SJ, Brendsel J (2006) Could the GI tract be a better portal for antibody therapy?Gut 55: 1681-1682.9.Plettenberg A, Stoehr A, Stellbrink HJ, Albrecht H, Meigel W (1993) A preparation from bovine colostrum in the treatment of HIV-positive patients with chronic diarrhea.Clin Investig 71: 42-45.10.Floren CH, Chinenye S, Elfstrand L, Hagman C, Ihse I (2006) ColoPlus, a new product based on bovine colostrum, alleviates HIV-associated diarrhoea.Scand J Gastroenterol 41: 682-686.©2007 Shawn J.Green.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.The author received no specifi c funding for this article.This letter is not intended to promote, endorse, or support the use of any currently available commercial sources of colostrum or "immune milk."Origo Bioscience Institute, a newly formed nonprofi t, is interested in the development of low-tech, low-cost technology platforms for the production and processing of "immune milk" from cows and goats to prevent and treat diarrheal illness and associated malnutrition in developing nations. Funding: